Prediction Score for Anticoagulation Control Quality Among Older Adults

Total Page:16

File Type:pdf, Size:1020Kb

Prediction Score for Anticoagulation Control Quality Among Older Adults Prediction Score for Anticoagulation Control Quality Among Older Adults The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Lin, Kueiyu Joshua, Daniel E. Singer, Robert J. Glynn, Suzanne Blackley, Li Zhou, Jun Liu, Gina Dube, Lynn B. Oertel, and Sebastian Schneeweiss. 2017. “Prediction Score for Anticoagulation Control Quality Among Older Adults.” Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease 6 (10): e006814. doi:10.1161/JAHA.117.006814. http://dx.doi.org/10.1161/ JAHA.117.006814. Published Version doi:10.1161/JAHA.117.006814 Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:34651988 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA SYSTEMATIC REVIEW AND META-ANALYSIS Prediction Score for Anticoagulation Control Quality Among Older Adults Kueiyu Joshua Lin, MD, ScD, MPH; Daniel E. Singer, MD; Robert J. Glynn, PhD, ScD; Suzanne Blackley, MA; Li Zhou, MD, PhD; Jun Liu, MD; Gina Dube, PharmD, CACP, RPh; Lynn B. Oertel, MS, ANP-BC, CACP; Sebastian Schneeweiss, MD, ScD Background-—Time in the therapeutic range (TTR) is associated with the effectiveness and safety of vitamin K antagonist (VKA) therapy. To optimize prescribing of VKA, we aimed to develop and validate a prediction model for TTR in older adults taking VKA for nonvalvular atrial fibrillation and venous thromboembolism. Methods and Results-—The study cohort comprised patients aged ≥65 years who were taking VKA for atrial fibrillation or venous thromboembolism and who were identified in the 2 US electronic health record databases linked with Medicare claims data from 2007 through 2014. With the predictors identified from a systematic review and clinical knowledge, we built a prediction model for TTR, using one electronic health record system as the training set and the other as the validation set. We compared the performance of the new models to that of a published prediction score for TTR, SAMe-TT2R2. Based on 1663 patients in the training set and 1181 in the validation set, our optimized score included 42 variables and the simplified model included 7 variables, abbreviated as PROSPER (Pneumonia, Renal dysfunction, Oozing blood [prior bleeding], Staying in hospital ≥7 days, Pain medication use, no Enhanced [structured] anticoagulation services, Rx for antibiotics). The PROSPER score outperformed SAMe-TT2R2 when predicting both TTR ≥70% (area under the receiver operating characteristic curve 0.67 versus 0.55) and the thromboembolic and bleeding outcomes (area under the receiver operating characteristic curve 0.62 versus 0.52). Conclusions-—Our geriatric TTR score can be used as a clinical decision aid to select appropriate candidates to receive VKA therapy and as a research tool to address confounding and treatment effect heterogeneity by anticoagulation quality. ( J Am Heart Assoc. 2017;6:e006814. DOI: 10.1161/JAHA.117.006814.) Key Words: anticoagulant • atrial fibrillation • quality control • stroke • venous thromboembolism itamin K antagonist (VKA; eg, warfarin) therapy is an measured by the time in therapeutic range (TTR), for which V effective anticoagulation option for stroke prevention in INR 2.0 to 3.0 is the standard therapeutic range for AF and patients with nonvalvular atrial fibrillation (AF) and for VTE.4–6 Patients on VKA with poor anticoagulation quality (ie, treatment and secondary prevention of venous thromboem- low TTR) have been shown to have a higher risk of bolism (VTE; including deep vein thrombosis and pulmonary thromboembolic and bleeding complications and thus a worse embolism).1–3 The safety and effectiveness of VKAs, however, risk–benefit ratio.4,7,8 depends on regular international normalized ratio (INR) Although clinical trials have shown that direct-acting oral monitoring and anticoagulation control quality, often anticoagulants (DOACs) are therapeutically advantageous over From the Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA (K.J.L., R.J.G., J.L., S.S.); Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA (K.J.L., D.E.S.); Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA (K.J.L., D.E.S., R.J.G., S.S.); Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA (L.Z.); Clinical and Quality Analysis, Information Systems, Partners HealthCare System, Boston, MA (S.B.); Clinical Informatics, Partners eCare, Partners HealthCare System, Boston, MA (L.Z.); Department of Pharmacy, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA (G.D.); Anticoagulation Management Service, Department of Nursing, Massachusetts General Hospital, Boston, MA (L.B.O.). Accompanying Data S1, Tables S1 through S7 and Figures S1, S2 are available at http://jaha.ahajournals.org/content/6/10/e006814/DC1/embed/inline-supple mentary-material-1.pdf Correspondence to: Kueiyu Joshua Lin, MD, ScD, MPH, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, 1620 Tremont St. Suite 3030, Boston, MA 02120. E-mail: [email protected] Received May 31, 2017; accepted August 23, 2017. ª 2017 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. DOI: 10.1161/JAHA.117.006814 Journal of the American Heart Association 1 Predicting Anticoagulation Control Quality Lin et al SYSTEMATIC REVIEW AND META-ANALYSIS Clinical Perspective Methods Data Source What Is New? We linked electronic health record (EHR) data from 2 large US • In patients aged ≥65 years, our prediction model for academic provider networks with Medicare claims data. The anticoagulation control quality outperformed the published first network consists of 1 tertiary hospital, 2 community score, SAMe-TT2R2. hospitals, 17 primary care centers, and 1 anticoagulation • ≥ Time in the therapeutic range was 70% (area under clinic that manages VKA-related care for all patients within the receiver operating characteristic curve 0.71 versus 0.57, a network. The second network includes 1 tertiary hospital, 1 significant difference.). community hospital, 16 primary care centers, and an anticoagulation clinic. Patients in network 1 were used as What Are the Clinical Implications? the training set for the prediction model derivation, and those • Our prediction score for anticoagulation quality can help in network 2 were used as the validation set. The EHR clinicians select the appropriate older adult candidates to database contains information on patient demographics, receive vitamin K antagonist therapy and can provide diagnosis and procedure codes, medications, lifestyle factors, researchers with a tool to adjust for confounding and to laboratory data, and various clinical notes. Both inpatient and investigate treatment effect heterogeneity due to predicted outpatient EHR data were used in this study. The Medicare anticoagulation quality. claims data contain information on demographics, inpatient and outpatient diagnosis and procedure codes, and dispensed or at least noninferior to VKAs,9–11 clinical equipoise still exists medications.26 This study was approved by Partners Health- when patients are likely to have good anticoagulation control Care Institutional Review Board (IRB). based on pretreatment characteristics.7,12 This choice is particularly difficult to make in older adults because DOACs have been associated with a higher risk of major gastrointesti- Study Population nal bleeding than VKAs in the older population.13–15 Moreover, In the linked Medicare claims–EHR data, we identified all chronic kidney disease is highly prevalent in older adults,16 patients aged ≥65 years with nonvalvular AF or VTE which makes lack of routine monitoring tests for DOACs a initiating a VKA from January 1, 2007, to December 31, challenge rather than an advantage because some DOACs are 2014, with no use of any oral anticoagulants (VKAs or substantially renally excreted (eg, 80% for dabigatran). Conse- DOACs) in the prior 90 days (new user design27). The VKA quently, it is critical to understand how patient characteristics initiation date was the index (cohort entry) date. The study are associated with anticoagulation quality so we can identify cohort was required to have at least 180 days of contin- the ideal candidates for VKA therapy. uous enrollment in Medicare inpatient, outpatient, and In the existing literature, there is only 1 published prescription benefits with at least 1 EHR encounter with prediction score for anticoagulation quality: the SAMe-TT2R2 date of service after January 1, 2007, and before the index score.17 It did not consider some clinically important predic- date. To ensure our ability to assess the primary outcome tors for TTR (eg, polypharmacy, hospitalizations, antibiotic reliably, patients were required to have at least 5 INR use)18–22 and was found to have suboptimal performance in values recorded in
Recommended publications
  • WO 2018/005606 Al 04 January 2018 (04.01.2018) W !P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/005606 Al 04 January 2018 (04.01.2018) W !P O PCT (51) International Patent Classification: KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, A61K 38/43 (2006.01) A61K 47/36 (2006.01) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, A61K 38/50 (2006.01) A61K 9/S0 (2006.01) OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, A61K 33/44 {2006.01) SC, SD, SE, SG, SK, SL, SM, ST, SV, SY,TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (21) International Application Number: PCT/US20 17/039672 (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (22) International Filing Date: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, 28 June 2017 (28.06.2017) UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (25) Filing Language: English TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (26) Publication Langi English MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (30) Priority Data: TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, 62/355,599 28 June 2016 (28.06.2016) US KM, ML, MR, NE, SN, TD, TG).
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Computational Antibiotics Book
    Andrew V DeLong, Jared C Harris, Brittany S Larcart, Chandler B Massey, Chelsie D Northcutt, Somuayiro N Nwokike, Oscar A Otieno, Harsh M Patel, Mehulkumar P Patel, Pratik Pravin Patel, Eugene I Rowell, Brandon M Rush, Marc-Edwin G Saint-Louis, Amy M Vardeman, Felicia N Woods, Giso Abadi, Thomas J. Manning Computational Antibiotics Valdosta State University is located in South Georgia. Computational Antibiotics Index • Computational Details and Website Access (p. 8) • Acknowledgements (p. 9) • Dedications (p. 11) • Antibiotic Historical Introduction (p. 13) Introduction to Antibiotic groups • Penicillin’s (p. 21) • Carbapenems (p. 22) • Oxazolidines (p. 23) • Rifamycin (p. 24) • Lincosamides (p. 25) • Quinolones (p. 26) • Polypeptides antibiotics (p. 27) • Glycopeptide Antibiotics (p. 28) • Sulfonamides (p. 29) • Lipoglycopeptides (p. 30) • First Generation Cephalosporins (p. 31) • Cephalosporin Third Generation (p. 32) • Fourth-Generation Cephalosporins (p. 33) • Fifth Generation Cephalosporin’s (p. 34) • Tetracycline antibiotics (p. 35) Computational Antibiotics Antibiotics Covered (in alphabetical order) Amikacin (p. 36) Cefempidone (p. 98) Ceftizoxime (p. 159) Amoxicillin (p. 38) Cefepime (p. 100) Ceftobiprole (p. 161) Ampicillin (p. 40) Cefetamet (p. 102) Ceftoxide (p. 163) Arsphenamine (p. 42) Cefetrizole (p. 104) Ceftriaxone (p. 165) Azithromycin (p.44) Cefivitril (p. 106) Cefuracetime (p. 167) Aziocillin (p. 46) Cefixime (p. 108) Cefuroxime (p. 169) Aztreonam (p.48) Cefmatilen ( p. 110) Cefuzonam (p. 171) Bacampicillin (p. 50) Cefmetazole (p. 112) Cefalexin (p. 173) Bacitracin (p. 52) Cefodizime (p. 114) Chloramphenicol (p.175) Balofloxacin (p. 54) Cefonicid (p. 116) Cilastatin (p. 177) Carbenicillin (p. 56) Cefoperazone (p. 118) Ciprofloxacin (p. 179) Cefacetrile (p. 58) Cefoselis (p. 120) Clarithromycin (p. 181) Cefaclor (p.
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • WO 2018/025248 Al 08 February 2018 (08.02.2018) W !P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/025248 Al 08 February 2018 (08.02.2018) W !P O PCT (51) International Patent Classification: Declarations under Rule 4.17: A61K 47/18 (2017.01) A61K 47/12 (2006.01) — of inventorship (Rule 4.1 7(iv)) (21) International Application Number: Published: PCT/IB20 17/054809 — with international search report (Art. 21(3)) (22) International Filing Date: — before the expiration of the time limit for amending the 05 August 2017 (05.08.2017) claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) (25) Filing Language: English (26) Publication Langi English (30) Priority Data: 201641026854 05 August 2016 (05.08.2016) IN (71) Applicant: JODAS EXPOIM PRIVATE LIMITED [IN/IN]; H.No: 8-2-293/82/A/1359, 1st Floor, Road No. 45, Jubilee Hills, Telangana, Hyderabad 500 033 (IN). (72) Inventors; and (71) Applicants (for US only): SINGH, Shashi Shanker Parsad [IN/IN]; H.No: 8-2-293/82/A/1359, 1st Floor, Road No. 45, Jubilee Hills, Telangana., Hyderabad 500 033 (IN). PATHIPATI, Venkataramana Rao [IN/IN]; H.No: 8-2-293/82/ A/1 359, 1st Floor, Road No. 45, Jubilee Hills, Telangana., Hyderabad 500 033 (IN). (74) Agent: SURAPUREDDY, Padmaja ; iProPAT Intellectual Property Solutions, 2nd Floor, Above Apollo Clinic, Suresh Square, Plot No 1-58/91/SS, Survey No 228 & 229/1, Mad- inaguda, Miyapur, Hyderabad 500
    [Show full text]
  • Chemistry Classification Pharmacokinetics Clinical Uses And
    Available online www.jocpr.com Journal of Chemical and Pharmaceutical Research, 2014, 6(11):28-58 ISSN : 0975-7384 Review Article CODEN(USA) : JCPRC5 Chemistry, classification, pharmacokinetics, clinical uses and analysis of beta lactam antibiotics: A review Mamdouh S. Masoud a, Alaa E. Ali b* and Nessma M. Nasr c aChemistry Department, Faculty of Science, Alexandria University, Alexandria, Egypt bChemistry Department, Faculty of Science, Damanhour University, Damanhour, Egypt cStudents’ Hospital, Alexandria University, Alexandria, Egypt _____________________________________________________________________________________________ ABSTRACT This review attempts to pinpoint the importance of betalactam antibiotics, which encompass penicillins, cephalosporins, cephamycins, carbapenems and monobactams from its chemistry, classification, pharmacokinetics, clinical uses and analysis. β- lactam antibiotics have been used for treatment of bacterial infections. Most antibacterials are chemically semisynthetic modifications of various natural compounds and classified on the basis of chemical /biosynthetic origin into natural, semisynthetic, and synthetic. Also, this classification system is based on biological activity; that antibacterials are divided into two broad groups according to their biological effect on microorganisms, bactericidal agents kill bacteria, and bacteriostatic agents slow down bacterial growth. Keywords: Beta lactam Antibiotics, Classification, Pharmacokinetics, Clinical uses, Analysis. _____________________________________________________________________________________________
    [Show full text]
  • Pharmaceutical Appendix to the Harmonized Tariff Schedule
    Harmonized Tariff Schedule of the United States (2020) Revision 8 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 8 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • WO 2011/089216 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date t 28 July 2011 (28.07.2011) WO 2011/089216 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 47/48 (2006.01) C07K 1/13 (2006.01) kind of national protection available): AE, AG, AL, AM, C07K 1/1 07 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) Number: International Application DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/EP201 1/050821 HN, HR, HU, ID, J , IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 2 1 January 201 1 (21 .01 .201 1) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (26) Publication Language: English TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 1015 1465. 1 22 January 2010 (22.01 .2010) EP kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, (71) Applicant (for all designated States except US): AS- ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, CENDIS PHARMA AS [DK/DK]; Tuborg Boulevard TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, 12, DK-2900 Hellerup (DK).
    [Show full text]
  • WO 2014/159510 Al 2 October 2014 (02.10.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/159510 Al 2 October 2014 (02.10.2014) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61P 37/02 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/US2014/023967 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 12 March 2014 (12.03.2014) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (25) Filing Language: English OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (26) Publication Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (30) Priority Data: ZW. 61/777,5 19 12 March 2013 (12.03.2013) US (84) Designated States (unless otherwise indicated, for every (71) Applicant: YALE UNIVERSITY [US/US]; Two Whitney kind of regional protection available): ARIPO (BW, GH, Avenue, New Haven, CT 065 11 (US). GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (72) Inventors: FLAVELL, Richard; 283 Moosewood Hill TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, Road, Guilford, CT 06437 (US).
    [Show full text]
  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
    BMJ Open: first published as 10.1136/bmjopen-2018-027935 on 5 May 2019. Downloaded from BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] http://bmjopen.bmj.com/ on September 26, 2021 by guest. Protected copyright. BMJ Open BMJ Open: first published as 10.1136/bmjopen-2018-027935 on 5 May 2019. Downloaded from Treatment of stable chronic obstructive pulmonary disease: a protocol for a systematic review and evidence map Journal: BMJ Open ManuscriptFor ID peerbmjopen-2018-027935 review only Article Type: Protocol Date Submitted by the 15-Nov-2018 Author: Complete List of Authors: Dobler, Claudia; Mayo Clinic, Evidence-Based Practice Center, Robert D.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2011) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2011) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Supplemental Material Etable 1. Variable Classification in EHR
    Supplemental Material eTable 1. Variable classification in EHR continuity cohort vs non-EHR continuity cohort mean capture proportion <60% mean capture proportion ≥60% Variable N (%) based N (%) based Stand Sensi- N (%) based N (%) based Stand Sensi-tivity on EHR on all data diff tivity on EHR on all data diff Dementia 4147 (4) 12577 (11) 0.28 0.33 1112 (5) 1350 (7) 0.05 0.82 Atrial fibrillation 8780 (7) 22493 (19) 0.34 0.39 2079 (10) 2315 (11) 0.04 0.90 Chronic lung disease 6643 (6) 25606 (21) 0.48 0.26 2901 (14) 3407 (17) 0.07 0.85 Chronic liver disease 2183 (2) 8961 (8) 0.27 0.24 1102 (5) 1355 (7) 0.05 0.81 Chronic kidney 4565 (4) 15638 (13) 0.34 0.29 2076 (10) 2372 (12) 0.05 0.88 disease Cancer 23113 (19) 56173 (47) 0.61 0.41 7260 (35) 8087 (40) 0.08 0.90 Diabetes 8225 (7) 27351 (23) 0.46 0.30 3975 (19) 4378 (21) 0.05 0.91 Hypertension 44097 (37) 98525 (82) 1.04 0.45 15796 (77) 16799 (82) 0.12 0.94 Anemia 7615 (6) 37210 (31) 0.67 0.20 3596 (18) 4674 (23) 0.13 0.77 Psychosis 1082 (1) 5486 (5) 0.23 0.20 396 (2) 557 (3) 0.05 0.71 Depression 4894 (4) 24721 (21) 0.52 0.20 2571 (13) 3290 (16) 0.10 0.78 Pneumonia 3220 (3) 11612 (10) 0.29 0.28 1102 (5) 1297 (6) 0.04 0.85 HIV 54 (0.05) 142 (0.1) 0.03 0.38 43 (0.2) 46 (0.2) 0.00 0.93 Fracture 1342 (1) 4135 (4) 0.16 0.32 391 (2) 457 (2) 0.02 0.86 RA 1260 (1) 4083 (3) 0.16 0.31 489 (2) 574 (3) 0.03 0.85 Ischemic stroke* 2335 (2) 5937 (5) 0.17 0.39 544 (3) 626 (3) 0.02 0.87 ICH* 1178 (1) 2117 (2) 0.07 0.56 229 (1) 256 (1) 0.01 0.89 MI* 324 (0.3) 1143 (1) 0.09 0.28 165 (1) 170 (1) 0.00 0.97 AKI*
    [Show full text]